Small Biotech Jumps On $100 Million Cancer Deal With Pharma Giant J&J

Small Biotech Jumps On $100 Million Cancer Deal With Pharma Giant J&J

Shares of Fate Therapeutics popped Friday after the biotech company announced a deal with Johnson & Johnson to develop cancer treatments in the immuno-oncology class of medicine.